ArticleCell reports. Medicine2024
Therapeutic avenues in bone repair: Harnessing an anabolic osteopeptide, PEPITEM, to boost bone growth and prevent bone loss.
Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A Dual-Bioresponsive and Programmable Microneedle Matrix as a Bioinspired Coupler for Orchestrating Diabetic Bone Regeneration.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- PEPITEM Regulates the Synovial Microenvironment During Immune-Mediated Inflammatory Arthritis to Limit Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Gut microbiota and bone aging: Focusing on the gut-X axis modes.Journal of orthopaedic translation · 2026Review
- Selenium Attenuates Dexamethasone-Induced Osteoblast Dysfunction and Prevents Femoral Head Osteonecrosis via PI3K/AKT/GSK3β Pathway Activation.Orthopaedic surgery · 2025Article
- Unraveling the Bone-Brain Communication Network.Biology · 2025Review
- Engineering Peptide Modulators for T-Cell Migration by Structural Scaffold Matching.Journal of medicinal chemistry · 2025Article
- The sustained-release agent of total flavonoids of Rhizoma drynariae prepared by nano-mesoporous silica can still promote osteogenesis and angiogenesis in vitro.Scientific reports · 2025Article
- Disease-Associated Signatures Persist in Extracellular Vesicles from Reprogrammed Cells of Osteoarthritis Patients.International journal of molecular sciences · 2025Article
- A bibliometric analysis of the current state and future directions of osteoporosis pharmacological treatment.Frontiers in medicine · 2025Article
- A Procedural Overview of the Involvement of Small Molecules in the Nervous System in the Regulation of Bone Healing.International journal of nanomedicine · 2025Review
- BMSC-derived exosomes improve rheumatoid arthritis by regulating Th17 cell differentiation through targeting PRDM1.Regenerative medicine · 2025Article
- Exploring the Biological Impact of β-TCP Surface Polarization on Osteoblast and Osteoclast Activity.International journal of molecular sciences · 2024Article
- iPSCs-derived iMSCs prevent osteoporotic bone loss and affect bone metabolites in ovariectomized mice.Journal of cellular and molecular medicine · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The existing suite of therapies for bone diseases largely act to prevent further bone loss but fail to stimulate healthy bone formation and repair. We describe an endogenous osteopeptide (PEPITEM) with anabolic osteogenic activity, regulating bone remodeling in health and disease. PEPITEM acts directly on osteoblasts through NCAM-1 signaling to promote their maturation and formation of new bone, leading to enhanced trabecular bone growth and strength. Simultaneously, PEPITEM stimulates an inhibitory paracrine loop: promoting osteoblast release of the decoy receptor osteoprotegerin, which sequesters RANKL, thereby limiting osteoclast activity and bone resorption. In disease models, PEPITEM therapy halts osteoporosis-induced bone loss and arthritis-induced bone damage in mice and stimulates new bone formation in osteoblasts derived from patient samples. Thus, PEPITEM offers an alternative therapeutic option in the management of diseases with excessive bone loss, promoting an endogenous anabolic pathway to induce bone remodeling and redress the imbalance in bone turnover.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.